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Abstract
The life expectancy of patients with schizophrenia is reduced by between 15 and 25 years. Those patients dying of natural causes die of the same
diseases as in the general population. In 2009 the World Health Organization (WHO) identified underlying global risk factors for mortality in the general
population. However, there is little evidence in the literature assessing their validity in those with schizophrenia. The WHO report on global health risks
(2009) identifies hypertension, smoking, raised glucose, physical inactivity, overweight and obesity, and high cholesterol as the six leading global
mortality risk factors. Currently, there are minimal data on the contribution to mortality that these risk factors make in schizophrenia, and their
optimum management. Both short and long-term studies are needed to address these gaps. New research has raised important questions about risk
balance with regards to ideal body mass, with some studies showing that being overweight is associated with lower all-cause mortality and lower suicide
rates. Cardiorespiratory fitness is being recognized as a more powerful predictor of mortality than smoking, hypertension or diabetes in men. However,
there are virtually no published data on assessment of fitness levels in schizophrenia. New studies have raised concerns about the quality of physical
care for patients with schizophrenia, which is another important avenue of future research. A greater biological understanding of the relationship
between these disorders and schizophrenia would inform clinical practice. Low birth weight has been associated with increased risk for schizophrenia,
and it will be important to explore this risk factor for both physical and mental health outcomes.
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Introduction
The World Health Organization (WHO) report on global
health risks identiﬁed 24 mortality risk factors (WHO,
2009). The six leading risks were, in order of priority, high
blood pressure, tobacco use, high blood glucose, physical
inactivity, overweight and obese, and high cholesterol.
Together, these six risk factors are responsible for raising
the risk of chronic disease and account for 42.1% of
global mortality. The relative importance of these risk fac-
tors varies across countries and by income group.
Understanding the role of these risk factors is pivotal to
developing a clear and eﬀective strategy for improving
global health.
In economically developed countries, people with schizo-
phrenia die 20–25 years prematurely (Kilbourne et al., 2009).
Much of this loss of life span is due to the same natural causes
(cancer, respiratory disease, heart disease, digestive disease,
etc.) as seen in the general population (Brown et al., 2000).
Although in the general population the relative contribution
of these risk factors to all-cause mortality and disease-speciﬁc
mortality is now well described (WHO, 2009), the relative
importance of these risk factors in schizophrenia is much
less well understood. There is some evidence to support the
view that schizophrenia may be a disease mimicking
accelerated ageing (Fernandez-Egea et al., 2009; Kirkpatrick
et al., 2008), which would suggest a need for reappraisal of
guidelines both for risk assessment and for optimum medica-
tion doses. A systematic review and two recent studies in
schizophrenia (Table 1) show the standardized mortality
ratios (SMRs) are raised for all-cause mortality and also
across disease categories of cancer, circulatory disease, respi-
ratory disease and digestive diseases. These ﬁndings support
the view that the relative contribution of risk factors to all-
cause mortality and by disease in schizophrenia is likely to be
diﬀerent to that in the general population. Guidelines for
physical health in schizophrenia are based on extrapolations
from the general population; however, the attributable risks
in schizophrenia for all-cause mortality and disease-speciﬁc
mortality have been minimally evaluated.
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rate of suicide in patients aged less than 40 years
(SMR¼8.38), followed by increased rates of cardiovascular
disease (CVD) (SMR¼1.10), respiratory disease
(SMR¼2.80), digestive disease (SMR¼1.85) and genito-
urinary diseases (SMR¼1.61) in older patients (Brown,
1997). To understand the mortality pattern in schizophrenia,
it will be important to examine the mortality risk of patients
by age group. For example, in the general population leukae-
mia is the most common cancer in people aged less than 40
years, whereas lung and breast cancer become the leading
killers in older patients (Jemal et al., 2008).
Our understanding of the genetics of schizophrenia is
incomplete, and more research is required to understand
metabolism of drugs and toxic chemicals such as carcinogens
in tobacco smoke in this patient population. There are likely
to be diﬀerences between the sexes and between ethnic
groups.
Recent studies in the general population suggest a re-va-
luation of accepted beliefs. Intentional weight loss seems to be
associated with increased mortality (Sørensen et al., 2005).
Low lipids are associated with frailty and increased mortality
(Okamura et al., 2008). Overweight has been shown to be
associated with the lowest risk of all-cause mortality (Flegal
et al., 2007; Tunstall-Pedoe et al., 1997) as well as lower sui-
cide rates (Gravseth et al., 2010; Magnusson et al., 2006). This
paper will explore some of these paradoxes and propose new
targets for future research.
Objective
The theme of this paper will be to explore whether the risk
factors for premature mortality in the general population are
directly relevant to people with schizophrenia. This will lead
to the identiﬁcation of new research targets in schizophrenia
which may help address the paradox of excess premature
all-cause mortality.
Method
A search was carried out in Medline, Embase and PsycINFO
using the following terms: schizophrenia and mortality and
modiﬁable (OR reduction OR intervention). The search was
conducted for the time period 1987 to January 2010. Papers
were included which examined the link between schizophrenia
and mortality, with reference to smoking, hypertension, dia-
betes, physical inactivity, overweight/obesity and lipids.
Papers which failed to separate out patients with schizophre-
nia from other mental disorders were excluded. Papers
included in this review were limited to systematic reviews
and meta-analyses when available; otherwise high-quality
studies were reported. In addition, the literature was non-
systematically reviewed to identify the leading mortality risk
factors in the general population and whether these risk fac-
tors can be reduced in patients with schizophrenia.
Results
The systematic literature search identiﬁed 974 papers.
Together with hand searches, 60 papers have been included
in this paper and the results are presented under the headings
mortality risk factors and antipsychotic medication.
Mortality risk factors
Hypertension. The WHO report on global health risks
highlights hypertension as the leading global risk factor for
mortality, accounting for 12.8% of deaths (WHO, 2009). A
US study, in just over 22,000 patients with schizophrenia,
showed that hypertension was an important risk factor for
cardiac mortality (Kilbourne et al., 2009). There are excellent
studies in the general population showing the beneﬁts and the
eﬀectiveness of treatments to lower blood pressure. There is
little in the literature examining the eﬃcacy of antihyperten-
sives in patients being treated with antipsychotics, some of
which target similar receptors. However, Piette et al. report
a study in 1686 veterans with schizophrenia and comorbid
diabetes and hypertension which examined the issue of med-
ication compliance (Piette et al., 2007). This study showed
that the adjusted odds of poor adherence were signiﬁcantly
higher for hypoglycaemic and antihypertensive medications
than for antipsychotic medication (both adjusted odds
ratios were 1.5, p<0.001). Antihypertensive therapy may be
associated with sexual dysfunction (Ferrario and Levy, 2002),
which is also a common adverse event associated with anti-
psychotics medications. The schizophrenia literature shows
that many patients have untreated hypertension. Therefore
it will be important to design studies in schizophrenia to accu-
rately assess incidence, issues of management of hypertension
and eﬀectiveness of treatments and, in the long term, the
Table 1. Standardized mortality ratios (SMRs) by disease category in schizophrenia
Causes of death
by disease category
SMR
(Saha et al., 2007)
(Systematic review)
SMR (% deaths)
(Tran et al., 2009)
(Prospective cohort study)
n¼3470, 11 years
SMR (% deaths)
(Brown et al., 2010)
(Prospective linkage study)
n¼370, 25 years
All-cause mortality 2.58 3.6 male/4.3 females (13.9%) 2.89 (44%)
Circulatory 1.79 SMR not reported (2.0%) 2.58 (15%)
Neoplasms 1.37 1.5 (2.25%) 1.49 (8%)
Respiratory 3.19 Not given 4.99 (7%)
Digestive 2.38 Not given 2.89 (2%)
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a simple project; however, in practice it would be a large
epidemiological study.
Smoking. Tobacco is the second most important global
mortality risk factor and accounts for 8.7% deaths globally
(WHO, 2009). Patients with schizophrenia have higher rates
of smoking than the general population (Catts et al., 2008;
Tran et al., 2009). Recent studies in schizophrenia have shown
that cardiac-related deaths are 12-fold higher in young smo-
kers relative to non-smokers: hazard ratio (HR)¼12.4,
p¼0.0005 (Kelly et al., 2009). Smoking approximately dou-
bles the rate of cancer deaths (Tran et al., 2009). In the gen-
eral population, smoking cessation has been associated with
signiﬁcant reduction in CVD risk and cancer deaths.
However, the results of smoking cessation programmes to
date in schizophrenia are poor (Campion et al., 2008).
There is evidence demonstrating that excess cancer and car-
diac mortality in schizophrenia is in part related to poor qual-
ity of physical treatments and late diagnosis (Kisely et al.,
2007, 2008; Laursen et al., 2009; Mitchell et al., 2009).
Smoking has also been linked with increased risk of suicide
(Malone et al., 2003). Prospective studies are needed to unra-
vel this complex area. Another issue which needs to be con-
sidered is the impact of smoking on heart rate variability,
which has already been shown to be abnormal in schizophre-
nia (Jindal et al., 2009). It will also be important to establish
whether two main carcinogenic components in cigarette
smoke, polycyclic aromatic hydrocarbons and the tobacco-
derived nitrosamines, have normal metabolism, as in the gen-
eral population, or whether this is impaired in patients with
schizophrenia, which will provide valuable insight into the
risk of lung cancer. The histology of lung cancer in the gen-
eral population has changed over the last 40 years from being
predominantly squamous cell carcinoma to adenocarcinoma,
but to date there is little information in the schizophrenia
literature on the histology of lung cancer. Mortality rates
for lung cancer are raised in schizophrenia (SMR¼2.65)
(Brown et al., 2010). However, a meta-analysis suggested
that the standardized incidence rates are lower in schizophre-
nia than in the general population, after controlling for smok-
ing (Catts et al., 2008).
Blood glucose. High blood glucose is the third most impor-
tant global risk factor for mortality and explains 5.8% of
global deaths (WHO, 2009). It is well established that patients
with schizophrenia and their families are at increased risk of
diabetes mellitus. A US study showed that diabetes is an
important risk factor for cardiac-related death in schizophre-
nia (Kilbourne et al., 2009). In the general population it has
been shown that low birth weight is a risk factor for diabetes
(Phillips et al., 1994). This study needs to be repeated in
schizophrenia, as this may prove a useful risk signal. The
management of diabetes in schizophrenia is less well estab-
lished than in the general population. However, one study has
reported that the management of diabetes in schizophrenia
does not alter the course of the illness at 3 years (Ascher-
Svanum et al., 2007). A community study showed better
control of diabetes in patients with schizophrenia than con-
trols (Dixon et al., 2004). However, some antipsychotic drugs
have been shown to reduce the eﬀectiveness of hypoglycaemic
medication in older patients (Pham and Dickman, 2007).
Kahn et al. found that ﬁrst-episode patients with schizophre-
nia present with high levels of abnormal glucose (Kahn et al.,
2008). Further, this study reported that antipsychotics were
associated with signiﬁcant worsening of glucose levels at 12
months. Piette et al. reported that 46% of patients with
schizophrenia and comorbid diabetes were taking at least
two or more medications to manage their diabetes (Piette
et al., 2007). These ﬁndings support the view that it would
be valuable to follow up patients with schizophrenia and
monitor the relationship between their mental illness, their
diabetes and treatment in relation to morbidity and mortality.
Physical fitness and inactivity. Physical inactivity
accounts for 5.5% of global deaths (WHO, 2009). There are
now several studies in the general population which show that
low physical ﬁtness, deﬁned in terms of cardiorespiratory ﬁt-
ness (CRF), better predicts CVD mortality than traditional
risk factors such as smoking, hypertension or diabetes in men
(Kodama et al., 2009; Myers et al., 2002). Furthermore, a
recent study of 22,817 patients with schizophrenia also
found that low physical activity had a higher HR than smok-
ing for heart disease mortality (HR¼1.66; 95% CI 1.59–1.74
versus HR¼1.32; 95% CI 1.26–1.39) (Kilbourne et al., 2009).
High CRF and muscle strength are not only associated with a
reduction in CVD mortality but also with all-cause mortality
(Lee et al., 1999; Ruiz et al., 2008). A study in young adoles-
cents with schizophrenia showed lower physical activity levels
and CRF than their peers (Koivukangas et al., 2010), which
supports the view that schizophrenia itself is linked to
increased mortality vulnerability. Low CRF is associated
with insulin resistance and other risk factors for CVD mor-
tality (Leite et al., 2009).
These ﬁndings raise several important research questions
in schizophrenia. For example, what is the best measure of
ﬁtness in patients with schizophrenia (resting heart rate,
treadmill test or questionnaire?). As there are virtually no
ﬁndings in schizophrenia, it will be important to mirror
some of the studies already performed in the general popula-
tion. These have examined long-term mortality and its asso-
ciation with ﬁtness, pre and post training. This approach is
important, as training people can improve their physical ﬁt-
ness and reduce their risk of CVD and all-cause mortality
(Blair et al., 1995). The association between CRF and insulin
resistance should also be explored in schizophrenia. The
WHO report also highlights ﬁtness as being highly protective
against breast and colon cancer in the general population
(WHO, 2009), so these cancers should be studied ﬁrst.
Overweight and obesity. An increased body mass index
(BMI) is the ﬁfth most important global risk factor for mor-
tality and accounts for 4.8% of global deaths (WHO, 2009).
However, the Monica study (Tunstall-Pedoe et al., 1997) and
an American study (Flegal et al., 2007) based on data analysis
from 2.3 million deaths show that overweight patients have
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those with ideal weight and the obese. Overweight and obesity
are major issues for patients with schizophrenia, and it is
important to establish how this impacts on all-cause and
CVD mortality in schizophrenia. A study from Sweden
found that, in the general population of 1.3 million army
recruits followed up to 31 years, compared with those with
a normal BMI, those who were overweight on recruitment
had a 15% lower suicide rate and the obese had a 30% reduc-
tion subsequently (Magnusson et al., 2006). A population-
based cohort study of 610,359 Norwegians, 1967–1976,
found that low body weight was a signiﬁcant risk factor
for suicide (Gravseth et al., 2010). A prospective study,
1986–2002, of 46,755 men showed that a higher BMI was
related to a reduced suicide mortality rate, from 52 per
100,000 person-years with a BMI of less than 21 to 13 per
100,000 person-years with a BMI of 30 or higher (Mukamal
et al., 2007). The literature is speculative regarding the possi-
ble mechanisms associated with this lowered suicide risk. It
may simply be correlational, with no causal link. However, as
suicide and accidental death are associated with 40% of the
deaths in schizophrenia, it is an important question to address
regarding the risk balance of overweight and obese categories
in schizophrenia. Moreover, suicides tend to occur in young
patients, so this has potentially more impact on their family
than later mortality. Two systematic reviews in schizophrenia
show that modest intentional weight loss can be achieved in
the short term, in both overweight and obese patients (Bushe
et al., 2009; Faulkner et al., 2007). However, there are studies
in older patients in the general population raising some con-
cerns about intentional weight loss (Adams, 2009). One well-
designed 18-year follow-up study shows a very signiﬁcant
increase in mortality (Sørensen et al., 2005). The relevance
of this in schizophrenia should be evaluated as soon as pos-
sible, as most patients will be overweight secondary to anti-
psychotic medication use. We were unable to ﬁnd studies in
schizophrenia which examined the relationship between BMI
and mortality.
Lipids. High cholesterol accounts for 4.5% of global deaths
(WHO, 2009). In the general population, familial hypercho-
lesterolaemia is a well-established risk factor for premature
mortality. The role of statins in the management of diabetes
and CVD are also well established in the general population.
However, there are emerging data that in older patients low
cholesterol may be associated with increased frailty and mor-
tality (Okamura et al., 2008; Ra ¨ iha ¨ et al., 1997). Recent
research has linked the use of statins with increased risk of
diabetes in the general population (Sattar et al., 2010), but to
date there are few data in the schizophrenia literature. As
patients with schizophrenia are at an elevated risk of devel-
oping diabetes, this may alter the risk–beneﬁt balance of
treatment with statins. Paradoxically, in patients who respond
to clozapine it has been reported that a reduction in the pos-
itive and negative symptom score (PANSS) correlates with
increases in lipid levels (Huang and Chen, 2005).
Kilbourne’s study in 22,817 patients with schizophrenia
(Kilbourne et al., 2009) showed that hyperlipidaemia was pro-
tective for CVD mortality (HR for mortality from heart
disease 0.86; 95% CI 0.82–0.89), whereas diabetes (HR¼
1.51; 95% CI 1.44–1.57) and hypertension (HR¼1.38; 95%
CI 1.32–1.46) both increased cardiac mortality risk.
Moreover, if schizophrenia is a disease mimicking rapid
ageing, it will be important to establish the best lipid levels
by age and their impact on mortality in this population. To
date there are only data from one study (Kilbourne et al.,
2009).
Medical care. Patients with schizophrenia are not engaged
with and tend to be treated poorly by health services
(Kreyenbuhl et al., 2009; Rethink, 2010). There is evidence
that people with schizophrenia are less likely to receive cancer
screening and secondary care interventions even if identiﬁed
with a disorder (Lawrence et al., 2000; Kisely et al., 2007,
2008). Even when a physical healthcare need is identiﬁed,
treatment is less intensive than in the general population.
Further research is needed to identify why this is so and
how it may be remedied.
Antipsychotic medication
The primary theme of this paper is to explore whether the
major risk factors for premature mortality in the general pop-
ulation are directly relevant and manageable in people with
schizophrenia. However, treatments for schizophrenia may
also aﬀect physical health, which may lead to early mortality.
This topic is complex, and here we present a summary of
some the most recent ﬁndings. A systematic review examining
the diﬀerential eﬀects on mortality of second-generation anti-
psychotics compared with ﬁrst-generation antipsychotics
showed inconsistent ﬁndings (Weinmann et al., 2009).
However, Tiihonen et al. describe one of the longest and larg-
est studies, examining cause-speciﬁc mortality in 66,881
patients with schizophrenia versus the total population of
Finland (5.2 million) between 1996 and 2006 (Tiihonen
et al., 2009). Long-term treatment with antipsychotics was
associated with lower mortality compared with no antipsy-
chotics (HR¼0.81: 95% CI 0.77–0.84). Their ﬁndings also
showed that for both clozapine and olanzapine, the two anti-
psychotics associated with greatest weight gain, there were no
signs of increased risk of death from ischaemic heart disease
after 7–11 years of cumulative exposure to these agents. A
Cochrane review of olanzapine versus other atypicals in
schizophrenia found no diﬀerential risk of death, although
olanzapine was associated with greater weight gain
(Komossa et al., 2010). A study in patients with tardive dys-
kinesia found higher rates of mortality in older patients, par-
ticularly those on conventional antipsychotics (Dean and
Thuras, 2009). Mortality studies which have not separated
out the schizophrenia cohort from patients with other
severe mental illnesses have not been included in this
review, as interpretation of these ﬁndings is complex
(Osborn et al., 2007; Ray et al., 2009).
Discussion
Patients with schizophrenia have an elevated incidence of the
six leading global mortality risk factors described by the
12 Journal of Psychopharmacology 24(11)WHO (WHO, 2009). If research ﬁndings from the general
population are directly applicable to schizophrenia, this
may account for the premature mortality associated with
the illness. However, there is little evidence in the literature
to support this assertion, or indeed refute it. Moreover, there
are indications that schizophrenia is a metabolic disease with
associated higher rates of diabetes, diﬀering patterns of adi-
posity and elevated lipids. Furthermore, low birth weight,
which is more common in those with schizophrenia, diabetes
and CVD, may be an early common pathway for this excess
mortality. Comorbidity is often associated with a poorer
treatment response for a variety of factors including adher-
ence, medication interactions and complications arising from
the underlying disorders.
Currently, there is a dearth of basic data for these impor-
tant parameters in schizophrenia. While some questions will
require long-term prospective studies, others may be more
amenable to shorter and less costly investigation. It will be
important to establish appropriate measures of CRF, and
how interventions to improve CRF impact on other risk fac-
tors in the short-to-medium term, such as insulin resistance,
obesity (including disposition) and hypertension.
Interrogation ofnationalprescribingdatabasesshouldallow
a retrospective view of the outcomes in treated hypertension,
dyslipidaemiaanddiabetes,inordertoascertainwhetherresults
are the same or diﬀer signiﬁcantly from the general population.
Giventhechronicunder-treatmentofthesedisorders,somecau-
tion would have to be exercised in interpreting the ﬁndings.
However, such studies could inform the design and feasibility
of prospective longer-term studies of interventions aimed at
both primary and secondary prevention.
There are suggestions that from the genetic perspective,
schizophrenia may confer advantages and disadvantages in
disease risk, such as elevated CVD but lower incidence of
autoimmune disorders (Eaton et al., 2006). A greater under-
standing of the relationship between these disorders at a
molecular level would be advantageous in advancing their
treatment. Such molecular understanding would also allow
us to understand whether carcinogens in cigarette smoke act
in precisely the same way irrespective of whether the smoker
has or does not have schizophrenia. Our review suggests that
direct extrapolation of results from the general population to
schizophrenia may not always be appropriate, and that opti-
mum treatment may require a compromise between physical
and mental health outcomes.
Since the introduction of atypical antipsychotics in the
1990s, there has been a debate about whether these drugs
might be associated with increased cardiovascular mortality
compared with typical antipsychotics, because of their ten-
dency for causing greater weight gain and metabolic changes.
Whereas smoking has now been strongly linked with a high
risk of cardiovascular mortality in schizophrenia (Kelly et al.,
2009; Kilbourne et al., 2009), the much larger study of anti-
psychotics with 7–11 years follow-up failed to show an
increased all-cause mortality or increased CVD mortality
with atypical antipsychotics compared with typicals
(Tiihonen et al., 2009). This supports the view that if there
is diﬀerential cardiovascular mortality risk between antipsy-
chotic classes, it is likely to be small and may require even
larger and longer studies to answer this question. These
ﬁndings may be partially explained by the observation that
weight gain in middle-aged and elderly individuals has a min-
imal impact on mortality at 14 years (Myrskyla ¨ and Chang,
2009). Further, Weiler et al. report that high-quality evidence
is now available from large cohort studies conﬁrming that
physical inactivity, rather than obesity, is the causal factor
for cardiovascular disease, coronary heart disease, type 2 dia-
betes, dyslipidaemias, hypertension, arrhythmias, increased
inﬂammatory markers, myocardial infarction, stroke, cancer
and ultimately death (Weiler et al., 2010). To date, there are
few research ﬁndings on the impact of antipsychotics on phys-
ical activity levels or cardiovascular ﬁtness in schizophrenia;
these studies need to be completed urgently.
Suicide and accidental deaths account for up to 40% of all
deaths in schizophrenia (Brown, 1997; Tran et al., 2009).
However, the schizophrenia literature has largely ignored the
impactofantipsychoticsonsuicideintheoverallmortalityrisk
balance equation for antipsychotics. A large Finnish study in
ﬁrst-admitted patientswith schizophrenia showed signiﬁcantly
increased risk for suicide in patients not receiving antipsy-
chotics (Tiihonen et al., 2006). Paradoxically, the literature
in the general population supports the view that patients
with a high BMI are at lower risk of suicide. This ﬁnding
may partially explain lower suicide rates with clozapine
(Hennen and Baldessarini, 2005) and may be relevant to all
antipsychotics. Studies are required to examine the link
between BMI and suicide risk in schizophrenia, which may
provide understanding into the risk factors for suicide and
improve management. A relatively simple population study
may help to address this hypothesis. Patients with schizophre-
nia tend to have higher BMIs in the US as compared with
Taiwan; as antipsychotics are used widely in both populations,
by examining the rates of suicide in these countries it may be
possible to see a diﬀerential impact of BMI on suicide risk by
population. This will be an important test of hypothesis.
Acknowledgements
The authors would like to thank Jan Yonge and Eli Lilly and
Company for their assistance with the literature search.
Funding
This research received no speciﬁc grant from any funding
agency in the public, commercial, or not-for-proﬁt sectors.
Conflict of interest
Hiram J Wildgust received lecture and consultancy fees from
Eli Lilly and Company. Mike Beary received lecture fees and
hospitality from Eli Lilly and Company. Richard Hodgson
received educational support and speaker fees from a number
of drug companies.
References
Adams KF (2009) Understanding long-term effects of weight loss.
Epidemiology 20: 849–850.
Ascher-Svanum H, Zhu B, Ernst FR, Faries DE, Jacobson JG and
Doebbeling CC (2007) The 3-year clinical and functional course
of schizophrenia among individuals with and without diabetes at
Wildgust et al. 13study entry. Primary care companion. J Clin Psychiatry 9:
122–128.
Blair SN, Kohl HW 3rd, Barlow CE, Paffenbarger RS Jr, Gibbons
LW and Macera CA (1995) Changes in physical fitness and all-
cause mortality. A prospective study of healthy and unhealthy
men. JAMA 273: 1093–1098.
Brown S (1997) Excess mortality of schizophrenia. A meta-analysis.
Br J Psychiatry 171: 502–508.
Brown S, Barraclough B and Inskip H (2000) Causes of the excess
mortality of schizophrenia. Br J Psychiatry 177: 212–217.
Brown S, Kim M, Mitchell C and Inskip H (2010) Twenty-five year
mortality of a community cohort with schizophrenia. Br J
Psychiatry 196: 116–121.
Bushe CJ, Bradley AJ, Doshi S and Karagianis J (2009) Changes
in weight and metabolic parameters during treatment with anti-
psychotics and metformin: do the data inform as to potential
guideline development? A systematic review of clinical studies.
Int J Clin Pract 63(12): 1743–1761.
Campion J, Checinski K and Nurse J (2008) Review of smoking
cessation treatments for people with mental illness. Adv Psychiatr
Treat 14: 208–216.
Catts VS, Catts SV, O’Toole BI and Frost AD (2008) Cancer
incidence in patients with schizophrenia and their first degree rel-
atives – meta-analysis. Acta Psychiatr Scand 117: 323–336.
Dean CE and Thuras PD (2009) Mortality and tardive dyskinesia:
long-term study using the US National Death Index. Br J
Psychiatry 194: 360–364.
Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown
CH, Wohlheiter K, et al. (2004) A comparison of type 2 diabetes
outcomes among persons with and without severe mental ill-
nesses. Psychiatr Serv 55: 892–900.
Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E,
et al. (2006) Association of schizophrenia and autoimmune dis-
eases: Linkage of Danish National Registers. Am J Psychiatry
163: 521–528.
Faulkner G, Cohn T and Remington G (2007) Interventions to
reduce weight gain in schizophrenia (Review). The Cochrane
Library Issue 3.
Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK,
Parellada E, Esmatjes E, et al. (2009) Telomere length and
pulse pressure in newly diagnosed, antipsychotic-naive patients
with nonaffective psychosis. Schizophr Bull 35: 437–442.
Ferrario CM and Levy P (2002) Sexual dysfunction in patients with
hypertension: implications for therapy. J Clin Hypertens 4:
424–432.
Flegal KM, Graubard BI, Williamson DF and Gail MH (2007)
Cause-specific excess deaths associated with underweight, over-
weight, and obesity. JAMA 298: 2028–2037.
Gravseth HM, Mehlum L, Bjerkedal T and Kristensen P (2010)
Suicide in young Norwegians in a life course perspective: popula-
tion-based cohort study. J Epidemiol Community Health 64:
407–412.
Hennen J and Baldessarini RJ (2005) Suicidal risk during treatment
with clozapine: a meta-analysis. Schizophr Res 73: 139–145.
Huang TL and Chen JF (2005) Serum lipid profiles and schizophre-
nia: effects of conventional or atypical antipsychotic drugs in
Taiwan. Schizophr Res 80: 55–59.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. (2008)
Cancer statistics, 2008. CA Cancer J Clin 58: 71–96.
Jindal R, Keshavan M, Eklund K, Stevens A, Montrose D and
Yeragani V (2009) Beat-to-beat heart rate and QT interval var-
iability in first episode neuroleptic-naive psychosis. Schizophr Res
113: 176–180.
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe
Y, Keet IP, et al. (2008) Effectiveness of antipsychotic drugs in
first-episode schizophrenia and schizophreniform disorder: an
open randomised clinical trial. Lancet 371: 1085–1097.
Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM,
Boggs DL, et al. (2009) Cigarette smoking and mortality risk in
people with schizophrenia. Schizophr Bull [Epub ahead of print,
Advance Access published on line December 17 2009,
doi:10.1093/schbul/sbp152].
Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF,
Dalack G, et al. (2009) Excess heart-disease-related mortality in a
national study of patients with mental disorders: identifying mod-
ifiable risk factors. Gen Hosp Psychiatry 31: 555–563.
Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E and
Bowie CR (2008) Is schizophrenia a syndrome of accelerated
aging. Schizophr Bull 34: 1024–1032.
Kisely S, Sadek J, MacKenzie A, Lawrence D and Campbell LA
(2008) Excess cancer mortality in psychiatric patients. Can J
Psychiatry 53: 753–761.
Kisely S, Smith M, Lawrence D, Cox M, Campbell LA and
Maaten M (2007) Inequitable access for mentally ill patients to
some medically necessary procedures. Can J Psychiatry 176:
779–784.
Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al.
(2009) Cardiorespiratory fitness as a quantitative predictor of all-
cause mortality and cardiovascular events in healthy men and
women: a meta-analysis. JAMA 301: 2024–2035.
Koivukangas J, Tammelin T, Kaakinen M, Ma ¨ ki P, Moilanen I,
Taanila A, et al. (2010) Physical activity and fitness in adolescents
at risk for psychosis within the Northern Finland 1986 Birth
Cohort. Schizophr Res 116: 152–158.
Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S,
Duggan L, et al. (2010) Olanzapine versus other atypical antipsy-
chotics for schizophrenia (Review). Cochrane Library Issue 3.
Kreyenbuhl J, Nossel IR and Dixon LB (2009) Disengagement
from mental health treatment among individuals with schizophre-
nia and strategies for facilitating connections to care: a review of
the literature. Schizophr Bull 35: 696–703.
Laursen TM, Munk-Olsen T, Agerbo E, Gasse C and Mortensen
PB (2009) Somatic hospital contacts, invasive cardiac procedures,
and mortality from heart disease in patients with severe mental
disorder. Arch Gen Psychiatry 66: 713–720.
Lawrence D, Holman CD, Jablensky AV, Threlfall TJ and Fuller
SA (2000) Excess cancer mortality in Western Australian psychi-
atric patients due to higher case fatality rates. Acta Psychiatr
Scand 101: 382–388.
Lee CD, Blair SN and Jackson AS (1999) Cardiorespiratory fitness,
body composition, and all-cause and cardiovascular disease mor-
tality in men. Am J Clin Nutr 69: 373–380.
Leite SAO, Monk AM, Upham PA, Chacra AR and Bergenstal
RM (2009) Low cardiorespiratory fitness in people at risk for type
2 diabetes: early marker for insulin resistance. Diabetol Metab
Syndr 1: 8.
Magnusson PK, Rasmussen F, Lawlor DA, Tynelius P and
Gunnell D (2006) Association of body mass index with suicide
mortality: a prospective cohort study of more than one million
men. Am J Epidemiol 163: 1–8.
Malone KM, Waternaux C, Haas GL, Cooper TB, Li S and
Mann JJ (2003) Cigarette smoking, suicidal behavior, and sero-
tonin function in major psychiatric disorders. Am J Psychiatry
160: 773–779.
Mitchell AJ, Malone D and Carney Doebbeling C (2009) Quality of
medical care for people with and without comorbid mental illness
and substance misuse: systematic review of comparative studies.
Br J Psychiatry 194: 491–499.
Mukamal KJ, Kawachi I, Miller M and Rimm EB (2007) Body
mass index and risk of suicide among men. Arch Intern Med 167:
468–475.
14 Journal of Psychopharmacology 24(11)Myers J, Prakash M, Froelicher V, Do D, Partington S and
Atwood JE (2002) Exercise capacity and mortality among men
referred for exercise testing. N Engl J Med 346: 793–801.
Myrskyla ¨ M and Chang VW (2009) Weight change, initial BMI, and
mortality among middle- and older-aged adults. Epidemiology 20:
840–848.
Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y,
Kita Y, et al. (2008) Lower levels of serum albumin and total
cholesterol associated with decline in activities of daily living and
excess mortality in a 12-year cohort study of elderly Japanese. J
Am Geriatr Soc 56: 529–535.
Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A and King
MB (2007) Relative risk of cardiovascular and cancer mortality in
people with severe mental illness from the United Kingdom’s
General Practice Research Database. Arch Gen Psychiatry 64:
242–249.
Pham CB and Dickman RL (2007) Minimizing adverse drug events
in older patients. Am Fam Physician 76: 1837–1844.
Phillips DI, Barker DJ, Hales CN, Hirst S and Osmond C (1994)
Thinness at birth and insulin resistance in adult life. Diabetologia
37: 150–154.
Piette JD, Heisler M, Ganoczy D, McCarthy JF and Valenstein M
(2007) Differential medication adherence among patients with
schizophrenia and comorbid diabetes and hypertension.
Psychiatr Serv 58: 207–212.
Ra ¨ iha ¨ I, Marniemi J, Puukka P, Toikka T, Ehnholm C and
Sourander L (1997) Effect of serum lipids, lipoproteins, and apo-
lipoproteins on vascular and nonvascular mortality in the elderly.
Arterioscler Thromb Vasc Biol 17: 1224–1232.
Ray WA, Chung CP, Murray KT, Hall K and Stein CM (2009)
Atypical antipsychotic drugs and the risk of sudden cardiac death.
N Engl J Med 360: 225–235.
Rethink (2010) Stigma and health services. Available at: http://
www.rethink.org/living_with_mental_illness/everyday_living/stig-
ma_mental_illness/stigma_and_1.html (Accessed 5 July 2010).
Ruiz JR, Sui X, Lobelo F, Morrow JR Jr, Jackson AW, Sjo ¨ stro ¨ mM ,
et al. (2008) Association between muscular strength and mortality
in men: prospective cohort study. Br Med J 337: 92–95.
Saha S, Chant D and McGrath J (2007) A systematic review of
mortality in schizophrenia. Arch Gen Psychiatry 64: 1123–1131.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen
AJ, et al. (2010) Statins and risk of incident diabetes: a collabo-
rative meta-analysis of randomised statin trials. Lancet 375:
735–742.
Sørensen TIA, Rissanen A, Korkeila M and Kaprio J (2005)
Intention to lose weight, weight changes, and 18-y mortality in
overweight individuals without co-morbidities. PLoS Med 2:
e171.
Tiihonen J, Lo ¨ nnqvist J, Wahlbeck K, Klaukka T, Niskanen L,
Tanskanen A, et al. (2009) 11-year follow-up of mortality in
patients with schizophrenia: a population-based cohort study
(FIN11 study). Lancet 374: 620–627.
Tiihonen J, Wahlbeck K, Lo ¨ nnqvist J, Klaukka T, Ioannidis JP,
Volavka J, et al. (2006) Effectiveness of antipsychotic treatments
in a nationwide cohort of patients in community care after first
hospitalisation due to schizophrenia and schizoaffective disorder.
Br Med J 333: 224–227.
Tran E, Rouillon F, Loze JY, Casadebaig F, Philippe A, Vitry F,
et al. (2009) Cancer mortality in patients with schizophrenia: an
11-year prospective cohort study. Cancer 115: 3555–3562.
Tunstall-Pedoe H, Woodward M, Tavendale R, Brook RA and
McCluskey MK (1997) Comparison of the prediction by 27 dif-
ferent factors of coronary heart disease and death in men and
women of the Scottish heart health study: cohort study. Br Med
J 315: 722–729.
Weiler R, Stamatakis E and Blair S (2010) Should health policy
focus on physical activity rather than obesity? Yes. Br Med J 340:
c2603.
Weinmann S, Read J and Aderhold V (2009) Influence of antipsy-
chotics on mortality in schizophrenia: systematic review.
Schizophr Res 113: 1–11.
WHO (2009) Global health risks: mortality and burden of disease
attributable to selected major risks. Geneva: World Health
Organization.
Wildgust et al. 15